Sorrento Therapeutics, Inc.
Chemically-Locked Bispecific Antibodies
Last updated:
Abstract:
Provided are bispecific antibody compounds having the Formula I: ##STR00001## wherein, FAB.sup.1, FAB.sup.2, and --X-- are as defined herein. The provided bispecific antibody compounds can be used a modulators of target molecules, including CD3, PSMA, CD19, CXCR5, CD33, PDL1, VEGFR2, cMet, or Axl, and are useful in the treatment of one or more conditions.
Status:
Application
Type:
Utility
Filling date:
26 Jan 2022
Issue date:
12 May 2022